Quarterly report [Sections 13 or 15(d)]

Significant Accounting Policies - Additional Information (Detail)

v3.26.1
Significant Accounting Policies - Additional Information (Detail)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 17, 2025
USD ($)
Apr. 30, 2025
USD ($)
Mar. 31, 2026
USD ($)
Segment
Product
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Subsidiary or Equity Method Investee [Line Items]              
General and administrative expenses     $ 431.4 $ 400.3      
Other current liabilities     563.7       $ 489.8
Cash outflow     113.8 0.2      
Credit card receivables     69.5       59.4
Bad-debt expense     0.1 0.0      
Allowance for doubtful accounts     1.7       1.8
Allowances for product returns     $ 2.0       2.0
Number of geographic regions | Segment     5        
Number of product categories | Product     5        
Other operating income     $ 5.5 0.0      
Minority interest increase           $ 6.2  
Secretariat of the federal revenue bureau of brazil [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Restricted cash     $ 15.2       $ 15.2
HBL Link Bioscience LLC [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Consideration to acquire assets   $ 6.5          
Ownership interest percentage   51.00%          
Link BioSciences Inc [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Cash paid   $ 6.5          
Asset acquisition contingent payments   0.0          
Reduction in cash   6.5          
Assets estimated fair value at the acquisition date   12.7          
Link BioSciences Inc [Member] | Goodwill [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Assets estimated fair value at the acquisition date   7.2          
Link BioSciences Inc [Member] | Software [Member] | Property Plant, and Equipment [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Assets estimated fair value at the acquisition date   2.5          
Link BioSciences Inc [Member] | Manufacturing Equipment [Member] | Property Plant, and Equipment [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Assets estimated fair value at the acquisition date   2.5          
Pruvit [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Consideration to acquire assets $ 19.0            
Pruvit [Member] | Developed Technology and Software [Member] | Property Plant, and Equipment [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Consideration to acquire assets 14.4            
Customer Relationships [Member] | Link BioSciences Inc [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Assets estimated fair value at the acquisition date   $ 0.5          
Customer Relationships [Member] | Pruvit [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Consideration to acquire assets 4.3            
Assembled Workforce [Member] | Pruvit [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Consideration to acquire assets 0.3            
Minimum [Member] | Contingent Milestone Payment Period [Member] | Pruvit [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Asset acquisition contingent payments 5.0            
Maximum [Member] | Contingent Milestone Payment Period [Member] | Pruvit [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Asset acquisition contingent payments $ 25.0            
Pro2col Software, LLC [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Equity interest percentage     5.00%        
Additional equity interest percentage     5.00%        
Proceeds from equity interest     $ 7.5        
Increased ownership percentage     10.00%        
Additional equity interest percentage to be acquired     10.00%        
Member compensation Liabilities [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Cash outflow       0.8      
Pro2col Health LLC [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Milestones period 10 years            
Additional payments $ 0.0            
Pro2col Health LLC [Member] | Contingent Milestone Payments Second [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Maximum milestone contingent payments 46.0            
Pro2col Health LLC [Member] | Minimum [Member] | Contingent Milestone Payments Third [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Contingent payments 5.0            
Pro2col Health LLC [Member] | Maximum [Member] | Contingent Milestone Payments First [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Contingent payments 2.0            
Pro2col Health LLC [Member] | Maximum [Member] | Contingent Milestone Payments Second [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Contingent payments 3.0            
Pro2col Health LLC [Member] | Maximum [Member] | Contingent Milestone Payments Third [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Contingent payments $ 15.0            
Reclassification [Member]              
Subsidiary or Equity Method Investee [Line Items]              
General and administrative expenses       31.6      
2018 Credit Facility [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Gain on extinguishment of debt         $ 2.5    
China [Member]              
Subsidiary or Equity Method Investee [Line Items]              
Other operating income     $ 5.5 $ 0.0